Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ariad Pharm Inc (ARIA) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 4,606,070
  • Shares Outstanding, K 192,710
  • Annual Sales, $ 118,800 K
  • Annual Income, $ -231,160 K
  • 36-Month Beta 2.09
  • Price/Sales 24.73
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.69 +102.74%
on 12/22/16
23.81 -0.46%
on 01/09/17
+11.56 (+95.22%)
since 12/19/16
3-Month
8.63 +174.62%
on 11/03/16
23.81 -0.46%
on 01/09/17
+12.89 (+119.24%)
since 10/19/16
52-Week
4.37 +442.33%
on 02/11/16
23.81 -0.46%
on 01/09/17
+18.43 (+349.72%)
since 01/19/16

Most Recent Stories

More News
Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Can The Uptrend Continue for ARIAD Pharmaceuticals (ARIA)?

Investors certainly have to be happy with ARIAD Pharmaceuticals, Inc. (ARIA) and its short term performance

Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of...

Jazz Begins Phase III Study for Label Expansion of Defitelio

Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease....

Becton, Dickinson Commercially Launches Precise WTA Kits

Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.

Baxter (BAX): Sluggish Macro Environment Mars Prospects

On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. (ARIA) Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited

Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ARIAD Pharmaceuticals, Inc. ("ARIAD"...

ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher

ArQule, Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 7% on the day.

ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk

On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).

Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and...

See More

Support & Resistance

2nd Resistance Point 23.75
1st Resistance Point 23.73
Last Price 23.70
1st Support Level 23.68
2nd Support Level 23.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.